# Satisfying REACH requirements with OpenTox

# Barry Hardy (Douglas Connect, Switzerland) OpenTox Coordinator

CADASTER Workshop Maribor, Slovenia 31 August 2011





# Introduction

OpenTox has developed an open semantic web for predictive toxicology. (2008-2011: Let's call it OpenTox 1.0)

Today I will: a)review the OpenTox 1.0 framework within the context of REACH; b)present some recent developments on OpenTox services and applications and what they can do.





#### The OpenTox Framework (reported 2010)

Collaborative development of predictive toxicology applications Journal of Cheminformatics 2010, 2:7 doi:10.1186/1758-2946-2-7

Barry Hardy, Nicki Douglas, Christoph Helma, Micha Rautenberg, Nina Jeliazkova, Vedrin Jeliazkov, Ivelina Nikolova, Romualdo Benigni, OlgaTcheremenskaia, Stefan Kramer, Tobias Girschick, Fabian Buchwald, Joerg Wicker, Andreas Karwath, Martin Gutlein, Andreas Maunz, Haralambos Sarimveis, Georgia Melagraki, Antreas Afantitis, Pantelis Sopasakis, David Gallagher, Vladimir Poroikov, Dmitry Filimonov, Alexey Zakharov, Alexey Lagunin, Tatyana Gloriozova, Sergey Novikov, Natalia Skvortsova, Dmitry Druzhilovsky, Sunil Chawla, Indira Ghosh, Surajit Ray, Hitesh Patel and Sylvia Escher

Most accessed paper in last year!

Open Access publication available at <a href="http://www.jcheminf.com/content/2/1/7">www.jcheminf.com/content/2/1/7</a>





#### Satisfying REACH Information Gathering Requirements

#### **Input Structure**



#### Out - Toxic or Not?

- □ LD50
  - Liver Toxicity
  - Secondary Metabolites
  - Bioavailability
  - Mutagenicity
  - Carcogenicity
  - ReproductiveToxicology
  - □ Skin Irritation
  - Aqua Toxicity
  - Combined predictions for arrays of mutiple end points



Driver Increasing demands on industry to satisfy safety
 evaluation and risk assessment required by
 REACH legislation. (Over 140k cmpds registered).





# With OpenTox approach to standards you can reliably gather information from multiple resources in real time...

Models - Mozilla Firefox						
ile <u>E</u> dit <u>V</u> iew Higtory	<u>B</u> ookmarks <u>T</u> ools <u>H</u> elp					
🕗 💽 - C 🗙	☆ I http://apps.ideaconsult.net:8180.	/ToxPredict/user/4	996263b-0d7c-4fe	c-8b68-15e38c29e7cd/A/step3	😭 🔹 🚼 • Google	م
🔵 Disablet 🚨 Cookiest 🛽	🛽 CSS+ 📰 Forms+ 🔳 Images+ 🕕 Informa	tion+ 🇐 Miscellar	neoust 🥒 Outlin	er 🕌 🖁 Resizer 🥔 Toolsr 🙆 View Sourcer 🍃	Options*	V 🔘 (
😹 Models	*					
ToxPre	dict					Welcome, guest Help Admin
Step 1: Search Select structure(s)		<b>3: Model<del>s</del></b> t prediction S	Step 4: E Estimate	Step 5: Results Display results	NEXT	$\rangle\rangle$
Endpoint	Model	Descriptors	Training dataset	Algorithm		
	Comparison of the service of the ser	MEG	@@@@ <mark></mark> # <b>! : : :</b>	http://opentox.informatik.tu-mu /OpenTox-dev/algorithm/kNNre	enchen.de:8080 gression	
Carcinogenicity	Monthead ToxTree: Benigni/Bossa rule: for carcinogenicity and mutagenicity	· -		ToxTree: Benigni/Bossa rules for mutagenicity	carcinogenicity and	
Dissociation constant (pKa)	₩ <sup>4</sup> ℤpKa	5		рКа		
Endpoints	ToxTree: Structure Alerts for the in vivo micronucleus assay in rodents			ToxTree: Structure Alerts for the assay in rodents	n vivo micronucleus	
Endpoints	Michael acceptors	124		ToxTree: Michael acceptors		
Eye irritation/corrosion	Matter Eye irritation	-		ToxTree: Eye irritation		
Human health effects	₩ ToxTree: Extended Cramer rules	1 <del>.</del>		ToxTree: Extended Cramer rules		
Human health effects	ToxTree: ILSI/Kroes decision tree for TTC	-		ToxTree: ILSI/Kroes decision tree	for TTC	
Skin irritation /corrosion	ToxTree: Skin irritation			ToxTree: Skin irritation		

Simple building of predictive toxicology applications based on well-established methods and databases



ToxPredict Developed by Ideaconsult



### ToxPredict accesses linked resources ...



Simple bui methods a

applicatio Distributed applications, integrating wide range of data, models, prediction methods





#### Or Taverna workflows can be run for more complex tasks..







# A Toxicology Ontology Roadmap

Submitted 31 Aug 2011: Barry Hardy (Douglas Connect and OpenTox), Gordana Apic (Cambridge Cell Networks), Philip Carthew (Unilever), Dominic Clark (EMBL-EBI), David Cook (AstraZeneca), Ian Dix (AstraZeneca & Pistoia Alliance), Sylvia Escher (Fraunhofer Institute for Toxicology & Experimental Medicine), Janna Hastings (EMBL-EBI), David J. Heard (Novartis), Nina Jeliazkova (Ideaconsult), Philip Judson (Lhasa Ltd.), Sherri Matis-Mitchell (AstraZeneca), Dragana Mitic (Cambridge Cell Networks), Glenn Myatt (Leadscope), Imran Shah (US EPA), Ola Spjuth (University of Uppsala), Olga Tcheremenskaia (Istituto Superiore di Sanità), Luca Toldo (Merck KGaA), David Watson (Lhasa Ltd.), Andrew White (Unilever), Chihae Yang (Altamira)

Based on Proceedings from the Toxicology Ontology Roadmap Workshop EMBL-EBI Industry Programme Workshop

16 -17th November 2010, Hinxton, UK





# **OpenTox - CADASTER Collaboration**

CADASTER web site uses applicability domain and substructure / similarity search facilities via the OpenTox API compliant web services, running at apps.ideaconsult.net:8080/ambit2

The applicability domain algorithms used are: apps.ideaconsult.net:8080/ambit2/algorithm?type=AppDomain

The results are displayed integrated within the Cadaster web database www.cadaster.eu/database/static/home.do





# **OpenTox - CADASTER Collaboration**

**Planned Developments:** 

1. Providing an OpenTox API wrapper for CADASTER Soap web services (Nina Jeliazkova, Ideaconsult)

2.Integrating CADASTER models in <u>ToxPredict</u>, via the OpenTox API wrapper (Nina Jeliazkova, Ideaconsult)

3.Provide access to selection of OpenTox models via CADASTER web site (Igor Tetko, Helmholtz Centre Munich)





# **REACH Requirements**







# **REACH and (Q)SAR bottlenecks**

Wim De Coen, ECHA, "Current Challenges from Evaluation Point of View - Introduction Case Studies", ECHA Experts Workshop on "Dealing with Uncertainty of Non-Test Methods under REACH" (2010):

Specific Bottlenecks for (Q)SAR:
Well standardized and accepted OECD principles
Issues mainly at level of documentation

- Level of documentation insufficient
  - QMRF, QPRF missing
- Applicability domain unclear
- Unclear training datasets & algorithm
  - General issue of lack of well established (Q)SAR software





# **REACH and data bottlenecks**

There exists considerable uncertainty in decision making based on current reproductive toxicity data, which place the largest potential demands on animal testing required by REACH.

Improvements to reduce uncertainty in decision making require: a "robust reference dataset of harmonised test information"

Reference: Dick Sijm and Betty Hakkert, RIVM, "Use of non-test methods in integrated testing strategies for making informed decisions - Non-test methods require robust reference datasets", ECHA Experts Workshop on "Dealing with Uncertainty of Non-Test Methods under REACH", 2010)





# (Q)SARs & REACH requirements

(Quantitative) Structure Activity Relationship = (Q)SAR

According to REACH Annex XI, (Q)SAR results may be used instead of testing when all of the following conditions are met:

•The results are derived from a (Q)SAR model whose scientific validity has been established.

•The substance falls within the applicability domain of the (Q)SAR model.

•The results are adequate for the purpose of classification and labeling and/or risk assessment.

•Adequate and reliable documentation of the applied method is provided.





### ToxCreate - (Q)SAR Model Building application





www.ToxCreate.org\_developed by In Silico Toxicology



# ToxCreate - (Q)SAR Model Results





© in silico toxicology 2009-2010, powered by OpenTox



	OECD Principle	OpenTox addresses Validation Principles by
1	Defined Endpoint	providing a unified source of well defined and documented toxicity data with a common vocabulary
2	Unambiguous Algorithm	providing transparent access to well documented models and algorithms as well as to the source code
3	Defined Applicability Domain	integrating tools for the determination of applicability domains during the validation of prediction models
4	Goodness-of-fit, robustness and predictivity	providing scientifically sound validation routines for the determination of errors and confidences
5	Mechanistic interpretation (if possible)	integrating tools for the inference, correlation or prediction of toxicological mechanisms and the recording of opinions and analysis in reports





# Validation within OpenTox



# **ToxCreate - linked to Validation Service**

	ht <u>C</u> hronik <u>L</u> esezeichen E <u>x</u> tras <u>H</u> ilfe		A	P 👧
S S - G X	http://opentox.informatik.uni	meinurg.de/validation	Google	~ 🧶
Crossvalidation re	ort × ÷			
Crossvalidation rep	ort			
Created at 03.24.2011				
	10.21			
Mean Results				
Table 1. Mean Result				
Crossvalidation u Algorithm uri	i <u>http://opentox.informatik.uni-freibu</u> <u>http://webservices.in-silico.ch/algor</u>		validation/50	
Dataset uri	http://webservices.in-silico.ch/algor			
Num folds	10	<u>10000</u>		
Num instances	51			
Num unpredicte	9			
Root mean squared				
Mean absolute en				
R square	0.42 +- 0.11			
Degraceion Dist				
Regression Plot	slot			
Regression Plot Figure 1. Regression				
Figure 1. Regression	olot Regression plot			
	Regression plot			
Figure 1. Regression				
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot			
Figure 1. Regression	Regression plot	7 8	8	





#### **ToxCreate - Confidence, Supporting Information**





© in silico toxicology 2009-2010, powered by OpenTox



# (Q)SARs - reporting in OpenTox



# (Q)SARs - QMRF reporting in OpenTox

le Edit S	Style	
QMRF	(Q)SAR	Model Reporting Format (QMRF), Version 1.2
Velcome	Version	1.2
==	Name	(Q)SAR Model Reporting Format
Section 1.	Author	Joint Research Centre, European Commission
Section 2.	Date	July 2007
<u>A</u>	Contact	Joint Research Centre, European Commission
ection 3.	Email	qsardb@jrc.it
Section 4.	www	http://ecb.jrc.ec.europa.eu/qsar/
Section 7.	is devise You are you in fi	Eingabe Please enter the URI for the download eiburg.de/validation/reach_report/QMRF/3 OK Abbrechen ei or reflect as much as possible the or consult the OECD "Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship Models. ei nvited to consult the OECD "Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship Models" that can aid illing in a number of fields of the QMRF (visit the following webpage for downloading the proper documentation: b.jrc.it/qsar/background/background_oecd_principles.php)
	lf you wi	sion Procedure ish to submit the QMRF for inclusion in the JRC QSAR Model Database, please save your QMRF as xml file and upload it by the on-line sion procedure





# **QPRF Reporting (Qedit)**

/home/chung/Desktop/phenobarn	
1. Substance 2. General Information 3. Prediction 4. Adequacy Info	
Model Prediction Applicability Domain	Compound Details
3.3. Applicability Domain Info.	Compound Details
Name Applicability Domain Estimation Algorithm Used :	URI: http://ambit.uni-plovdiv.bg:8080/ambit2/compound/5100/conformer/510(
Link to Applicability Domain Resource :	Smiles: [Ca+2].CCC1(C(=0)NC(=NC1=0)[0-])C2=CCCCC2.CCC3(C(=0)NC(=NC3=
	InChl:
3.3.b. Structural Analogues	InChI Key:
	CAS number: 143-76-0
Add Compound Remove Clear List Similarity Level: 0.95 Acquire List of Analogues Compound Info	Chemical Name: calcium bis[5-(1-cyclohexen-1-yl)-5-ethylbarbiturate]
List of Structural Analogues (URIs) : Image of structural analogue 3.3.c. Consideration	Einecs: 205-610-2
Chemical Name Experimental Value	REACH Reg. Date:
phenobarbital,Phen	Available Conformers (Links):
primidone,Primaclo calcium bis[5-(1-cyc	http://ambit.uni-plovdiv.bg:8080/ambit2/compound/5100/conformer/5100 http://ambit.uni-plovdiv.bg:8080/ambit2/compound/5100/conformer/105301
S-ethyl-5-(4'-hydrox barbexaclone 1,3-dimethyl-5-phen	http://ambit.uni-plovdiv.bg:8080/ambit2/compound/5100/conformer/181274
S-ethyl-5-phenylbar	
Discussion	
Applicability Domain Result: 🛷	
3.3.a. Choose Domain : Metabolic Domain	

Application by Pantelis Sopasakis (NTUA)





# Metabolites

According to ECHA Guidance B, further investigation may be required for degradation products and metabolites if considered relevant for the chemical safety assessment, PBT assessment or classification and labeling.

Metabolites, Metabolic Enzymatic induction and the creation of Reactive Intermediates may all lead to toxicity, e.g., in drug-drug interactions and hepatotoxic adverse events.





#### SMARTCyp Service for Predicting Metabolites



#### SMARTCyp

1. Assign Energies By SMARTS matching



Atom	SMARTS	Energy
1	[CX3H1](=O)[#6]	40.2
2	[CX4][N]	39.8
3	[N^3][H1,H2]	54.1

- 2. Compute Accessibility Descriptor
- A<sub>i</sub> = Maxbonds<sub>i</sub> / Maxbonds<sub>all</sub>

H<sub>2</sub>N  $\stackrel{1}{\longrightarrow}_{0}$  A<sub>1</sub> = 2 / 3 = 0.67 H<sub>2</sub>N  $\stackrel{2}{\longrightarrow}_{0}$  A<sub>2</sub> = 2 / 3 = 0.67 H<sub>2</sub>N  $\stackrel{3}{\longrightarrow}_{0}$  A<sub>3</sub> = 3 / 3 = 1.00

3. Compute Score and Rank Atoms

Score, S = E - 8A Lowest score gets rank 1

$$S_1 = 40.2 - 8*0.67 = 34.84$$
Atom 1 - Rank 2 $S_2 = 39.8 - 8*0.67 = 34.44$ Atom 2 - Rank 1 $S_3 = 54.1 - 8*1.00 = 46.10$ Atom 3 - Rank 3

### SmartCYP Prediction of Testosterone Metabolites



# **Metabolites**







### **Bioclipse Visualisation Workbench**



O. Spjuth, L. Carlsson, M. Eklund, E. Ahlberg Helgee, and Scott Boyer. Integrated decision support for assessing chemical liabilities.





#### **Bioclipse Visualisation Workbench**



O. Spjuth, L. Carlsson, M. Eklund, E. Ahlberg Helgee, and Scott Boyer. Integrated decision support for assessing chemical liabilities.





#### **Bioclipse Visualisation Workbench - OpenTox**



O. Spjuth, L. Carlsson, M. Eklund, E. Ahlberg Helgee, and Scott Boyer. Integrated decision support for assessing chemical liabilities.









Extension of ToxPredict to Read Across by Nina Jeliazkova (Ideaconsult)















		Wozilla Firefox Eile Edit View Higtory Bookr						l
		💽 🔄 🗠 🕜	🐴 🖌 http://localhost:808	15/vtox#Toxicity			☆ - 🔚 - 4	thembl id
		🧭 Disable- 👤 Cookies- 🗡 CS	🚱 🚊 Forms* 🔯 Images* 🌐	Information* 🚨 Miscellaneous* ,	🖋 Outline* 💷 Resize* ≿ Tools	- 🔄 View Source+ 🔝 Option	ns*	
		Attp://localhost:8085/vtox*	Login +					
		Help						ToxPrec
Carcinogenicity		Page 0	how identifiers 🗊 Show data 🗊	Show pradictions Bus models	Download			WELCOME GIEST
.Dataset								
CAS					57-	55-6		
Canc					1	.00		
Mouse_Female_Canc					N	ID		
Mouse_Female_NTP					N	ID		
Mouse_Male_Canc					N	ID		
Mouse_Male_NTP						ID		
Rat_Female_Canc					1	.00		
Rat_Female_NTP					N	ID	•••••• <u>•</u> •••••••••••••••••••••••••••••	
Rat_Male_Canc						.00	Í	
Rat_Male_NTP					N	D		
Reference						DB		
SAL					1	.00	<b>1</b>	
Model								
Potential S. typhimurium								
TA100 mutagen based on	NO	NO		NO	N	0		NO
QSAR								
Potential carcinogen based	NO	NO		NO	N	0		NO
on QSAR	NO	110		NO		10		NO
Structural Alert for genotoxic	NO	NO		NO	N	0		NO
carcinogenicity								
Structural Alert for	NO	NO		NO	N	0		NO
nongenotoxic carcinogenicity								
Unlikely to be a S.	NO	NO		NO				NO
typhimurium TA100 mutagen based on QSAR	NO	NO		NO	N	0		NO
Unlikely to be a carcinogen								
based on QSAR	NO	NO		NO	N	0	NO	
EPA Integrated Risk Information	Svetom (IDIC) Tovisite	L. Doviour Data						
		Review Data						
Inhalation_RfC_Assessed								1.00
Inhalation_RfC_Confidence								Medium
Inhalation_RfC_CriticalEffects			NO	NO	NO	NO	mild rev	ersible sedati
		identified. Alert for SN2 identified.	NO	NO	NO	NO	NO	
24		Alert for SNAr Identified. Alert for Schiff base	NO	NO	NO NO	NO	NO	
enTox		formation identified. No skin sensitisation alerts	YES	YES	YES	YES		
ion ov 🛩		identified.	YES	YES	YES	YES	YES	



# Chemical Space Visualisation (Ches-Mapper)

toping:

he dataset is presented in a 3D viewe



#### **CheS-Mapper: Chemical Space Mapping and Visualization in 3D** http://opentox.informatik.uni-freiburg.de/ches-mapper



#### Martin Gütlein<sup>1\*</sup>, Andreas Karwath<sup>1</sup>, Stefan Kramer<sup>2</sup>

\*guetlein@informatik.uni-freiburg.de

<sup>1</sup>Institute for Computer Science • Albert-Ludwigs-Universität Freiburg • Germany, <sup>2</sup>Institute for Computer Science II2 • Technische Universität München • Germany

#### Abstract

Scientific researchers in the field of chemoinformatics, are often overwheimed by the size and the sheer comple-chemical detects. Therefore, the need for visualization tools, ices or the uttremost repeats. The second s e compounds. These features can be highlighted within CheS-Mapper, which aids the chemist to better inderlying scientific knowledge. As a final function, the tools can also be used to select and export specifi atset for further analysis.

ni freihurn de/ches

**Chemical Space Mapping** 





**3D Visualization** 

Suitable for novice and expert users Single Steps: - Load dataset - Build 3D structure - Extract features - Clustering - 3D Embedding - 3D Embedding - 3D Embedding	~	Los II (2006a de la composición de la composició		1. 1. 1. (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	Constant Constant
Automatic detection and plug in of new methods and algorithms		( cand	and the second	-	Burt And also

Wizard Dialog to Control Mapping

A wizard dialog guides through the Ampping process

#### **Build 3D Structure and 3D Embedding Dataset Overview -- Clusters Inside Cluster View Extract Features** (of Clusters & Compounds) Select input dataset Dataset can be directly loaded from the web structure is built . asets are separated into clusters, arranged in 3D space intuitive interface of the 3D viewer allows to: Zoom/rotate the clusters Get valuable information on clusters via mouse over By selecting a cluster, the view zooms into the duster and displays compounds included Details for each compound are available via mouse over Like the clusters, the compounds are embedded into the 3D the position/ distance between compounds within the duste **Cluster Compounds 3D Alignment of Compounds** e a cluster by clicking on it distance hetwee en compounds he removed from the dataset ounds in the dataset are assigned to subgroup Compounds in a duster are likely to share from the dataset ton subgraphs: his subgraph is already available if ructural clustering is performed ternatively, the maximum common herath can be computed within as t. **Highlight Features and Endpoints** nd properties can be highlighted: unds are colored according to the numeric value, a high value is indicated npound is single cluster 'ally merge similar cluster Clustering groups that share structural similarity ounds are assigned to clusters when exists a common subgraph of sufficien ion towards the quality of the clustering approad plug in new duster algorithms **Open-Source Webstart Application** References Acknowledgements This work has been supported by the EU FP7 project (HEALTH-F5-2008-200787) OpenTox (http://www.opentox.orn). va program that comes in two variants: Java Web Start application (can directly started from a web browser) Local installation that makes use of non-java libraries Seeland, M, Girschick, T, Buchwald, F, Kramer, Online Structural Graph. Clustering Using Frequent Subgraph Mining, 2010, Machine Learning and Knowledge Discovery in Databases, 1.13K 213--228, Springer [21 Jmol: an open-source Java viewer for chemical structures in 3D. http://www.jmol.org

Developed by Martin Gütlein, Andreas Karwath, Stefan Kramer (ALU & TUM)





# Chemical Space Visualisation (Ches-Mapper)


## Forming chemical feature-based categories







## **Controlling Access to Confidential Information**

- OpenTox makes resources available through URIs
- OpenTox provides facilities to protect confidential information located at URIs. Two tasks are involved here:
  - Authentication: Confirming the identity of the user requesting access
  - Authorisation: Granting the confirmed identity access according to a set of restrictions described in policies





## Authentication



- Registered users are instantly available as potential users of OpenTox web services
- Users receive a token upon service request





## Authorisation



- Tokens encode user identity
- Tokens are valid for a certain time period only (customizable)
- The triplet URI+Action+Token makes up the call to be authorised
- All messages are encrypted (SSL)
- Resource Owners create and modify policies defining access rules





#### **Policies** Visual Paradigm for UML Community Edition (not for commercial use) Chemistry Lab Staff Policy for the resource http://myserver.com/resource/2435 allow allow John Mary allow the guest is allowed only to access the representation of the resource. POST GET \_ \_ \_ PUT allow allow Creator allow Guest OpenTox developers The creator/owner of the resource might be allowed to apply any HTTP request. allow allow OpenTox developers are not allowed to modify

### Validation against Confidential Data Case implemented Spring 2011



(PUT) the resource

Helen

George Loto



## **OpenTox - Leadscope Integration**

🖆 Compare 🛛 💥 🤹 🚍 🔯 Str	ructures 🛛 🍓 Eeature Combinations 🤉	_usters _caffolds R-Groups	ldd to Hierarchy						
Salmonella									
Histogram Scatterplot Features									Filters: Salmon Choose
/ Axis:	Salmonella Ď								
Sorted Feature List	✓			5	Mean 2	2-Score I	Filtered	Total	
nitro					0.79	19.9	660	660	
mitro, aryl-					0.81	19.9	606	606	
benzene, 1-nitro-					0.79	17.9	542	542	
nitro, phenyl-					0.79	17.9	542	542	
benzene, 1-heteroamino-					0.76	17.5	617	617	
benzene, 1,2,3,4-fused					0.85	14.5	275	275	
benzene, 1,2-fused					0.65	12.7	702	702	
					0.67	11.2 11.0	485 364	485 364	
					0.71	11.0	364	364	
					0.85	10.4	364	364	
aromatic					0.48	9.9	3286	3286	
naphthalene, 1-heteroamino-					0.94	9.8	88	88	
naphthalene, 1-nitro-					0.94	9.8	88	88	
					0.72	9.3	235	235	
halide, p-alkyl-					0.73	9.2	215	215	
naphthalene, 2-heteroamino-					0.96	8.8	68	68	
naphthalene, 2-nitro					0.96	8.7	67	67	
					0.57	8.6	781	781	
quinoline, 3-fused ring					0.88	8.5	89	89	
chloride, alkyl					0.68	8.3	254	254	
quinoline, 2-fused ring					0.87	8.2 8.2	86 144	86 144	
					0.58	8.2	608	608	
naphthalene, 1-alkyl-					0.38	8.0	119	119	
-halide, alkyl, acyc-					0.63	7.9	379	379	
benzene, 1,2,3-fused, 4-acyc					0.91	7.7	64	64	
					0.91	7.7	65	65	
-1,4-benzoguinone					0.77	7.7	120	120	
ketone, diphenyl					0.73	7.5	153	153	
pyridine, 3-fused ring-					0.66	7.4	241	241	
pyridine, 2-fused ring-					0.67	7.2	213	213	
halide, alkyl					0.60	7.1	405	405	
benzene, 1-(2-oxyethyl)-,2-oxymethyl-					0.95	7.0	44	44	
naphthalene, 2-alkyl-					0.77	7.0	104	104	
benzene, 1,3-dinitro-					0.84	6.8	68	68	
naphthalene, 1-phenyl-					0.89	6.7 6.7	53 58	53 58	
					0.60	6.7	181	181	
naphthalene, 2-(alkyl, cyc)-			-		0.88	6.6	52	52	
-1,4-naphthoguinone					0.75	6.6	101	101	
benzene, 1-aryl-,4-heteroamino-					0.95	6.4	38	38	
benzene, 1-amino-,3-heteroamino-	<b>1</b>				0.88	6.4	50	50	
					0.89	6.4	47	47	
mitroso					0.80	6.4	74	74	
-1,4-naphthoquinone, 5-hydroxy-	Image: 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1				0.83	6.3	60	60	
< >	1 10	100	ık	10K					Color by: Salmonella
Find:	2		X: Logarithmic 🔽						









## Analysis of Adverse Events Based on Pharmacological Activity



- Cardiac adverse events
- Related to hERG ion channel?

cyan = adverse event, red = drug lines define links



- Are the adverse events a function of inhibiting the pharmacological target?
- Or is the adverse event due to an off-target activity?







## **Example: Cardiac Adverse Events**



## **REACH and Weight of Evidence**

Within the REACH legislation, the so-called Weight of Evidence (WoE) approach is a component of the decision-making procedure on substance properties and thus an important part of the chemical safety assessment. In the legal text the use of weight of evidence approach is provided for in Annex XI as an option to meet the information requirements of Annexes VII to X.

According to the ECHA Guidance B the weight of evidence (WoE) approach is not yet a scientifically well-defined term or an agreed formalised concept. It involves assessing the relevance, reliability and adequacy of each piece of available information, holding the various pieces of information up against each other and reaching a conclusion on the hazard. This process always involves expert judgement. It is important to document and communicate how the evidence-based approach was used in a reliable, robust and transparent manner.





## **REACH and Weight of Evidence**

The ECHA Practical Guide 2 "How to report weight of evidence" (ECHA PG2) defines WoE as an evidence based approach involves an assessment of the relative values/weights of different pieces of the available information that have been retrieved and gathered in previous steps. To this end, a value needs to be assigned to each piece of information. These weights/values can be assigned either in an *objective* way by using a formalized procedure or by using expert judgement. The weight given to the available evidence will be influenced by factors such as the quality of the data, consistency of results, nature and severity of effects, relevance of the information for the given regulatory endpoint. One definition for weight of evidence is: 'the process of considering the strengths and weaknesses of various pieces of information in reaching and supporting a conclusion concerning a property of the substance.'





## **REACH and Weight of Evidence**

Within Weight of evidence is closely linked to *integrated testing/information strategies (ITS)*, in that the available evidence can help to determine the possible subsequent testing steps. The WoE approach may be applied if there is sufficient information from **several independent sources** leading to the conclusion that a substance does or does not have a particular dangerous property, while the information from each single source alone is regarded insufficient to support this notion (ECHA Evaluation 2010).

If any of the Annex XI conditions for (Q)SAR for waiver are not met, the (Q)SAR results cannot be used instead of testing but they may be used as a part of a Weight of Evidence approach.

When data from a single secondary source is used, it is essential to provide further supporting evidence e.g. QSAR predictions, manufacturing data, data taken from material safety data sheets, etc. All relevant information for the hazard endpoint should be addressed and a justified weight should be assigned to it in the overall assessment. (ECHA Evaluation 2010)





## Proposed Paper (s): Satisfying REACH Alternative Testing Information Requirements

- **1** Supporting Information Gathering & Evaluation
- 2 Data Sourcing and Integration

**3** (Q)SARS (including Applicability Domain, Validation, QMRF, QPRF reporting, Reliability, Confidence)

- 4 Categories and Read Across
- 5 Weight of Evidence (REACH and WoE could be a focus paper itself)
- 6 Predicting Metabolites
- 7 Achieving Harmonisation through Ontologies

Preparation Timeframe Sept-Nov 2011.

Interested in Collaborating on this paper?







## Initial Experience on SAM VO

### **Scientists Against Malaria (Pilot initiated June 2010)**

Using a low budget approach, strong interdisciplinary collaboration and innovative infrastructure and modelling developments, we moved a green field drug discovery project on a novel parasitic kinase target with no initial solved structure or known ligand at the start of the Pilot Project to Dose Response characterised leads within 9 months.

We are now extending chemical and kinome space exploration of activity relationships and developing schemes for toxicity profiling and prioritisation of compound libraries.





# SAM Virtual Organisation targeting Plasmodium Kinases (www.ScientistsAgainstMalaria.net)



## **Collaborative Research Framework Integration**







## **Event Driven Collaboration Architecture**

### **OpenToxLink ICT Architecture**







## **Processing Complex Events Stream**



## **Event Driven Weight of Evidence**







## Synergy Drug Design Collaboration Pilot



## The OpenToxLink Virtual Organisation

1

2

3

4

5

6



- Data Mining of Human Adverse Drug Events
- Data Mining of Literature Knowledge
  - Creation of Mechanism-based Hypothesis
    Selection of Biological Pathways & Targets
  - Selection of Compounds
  - Prediction of Metabolites of Compounds
  - Selection of *in vitro* assays relevant to Mechanism
- Selection and integration of Toxicity Data
  - Creation of Predictive Toxicology Model including Model Validation and Applicability Domain
  - Selection of Low and High Content Assays for Testing in Cell Lines
- Analysis of Results



## Weight of Evidence driven Prioritisation

A Weight-of-Evidence Approach to Prioritisation based on Consensus across Multiple Sources of Information

Roman Affentranger and Barry Hardy, Douglas Connect, Switzerland Glenn Myatt, Leadscope, USA Nina Jeliazkova, IdeaConsult, Bulgaria Matthew Clark and Jeff Wiseman, Pharmatrope, USA

We present the results of initial work carried out within the OpenToxLink Virtual Organization, applying a Weight-of-Evidence (WoE) approach based on consensus across multiple sources of information for the prediction of adverse effects of a large set of potential antimalarial compounds. The work was carried out as part of the EU FP7 project SYNERGY, evaluating the support of decision dashboards and event-driven collaborative research of software developed within SYNERGY. ...

Poster presented at OpenTox 2011, Munich

www.opentox.org/meet/opentox2011/posters/a-weight-of-evidence-approach-toprioritisation-based-on-consensus-across-multiple-sources-of-information





# The TCAMS MalariaBox

"Malaria Box": A collection of chemical compounds active against (i.e. inhibiting growth of) the malaria parasite Plasmodium falciparum

Data provided that is relevant for this project:
Activity against (growth inhibition of) P. falciparum strain 3D7 (common strain)
Activity against (growth inhibition of) P. falciparum strain DD2 (multi-drug resistant strain)
Cytotoxicity against (growth inhibition of) human hepatocytes, HepG2 (hepatoma cells)



## Human Adverse Events Data



Event-dru	Ig pair values in Titanium Predictions:
0	: no association (0)
0.35-0.4	: non-significant association (0)
> 0.4	: significant association (1)
Combinat	tion Rule for Event Groups:

Associate a drug with a group if the sum of individual event values is larger of equal to 0.4.

Adverse Event Groups	Group Name
Hepatic function abnormal Liver disorder	FuAbn
Hepatic necrosis	Nec
Cytolytic hepatitis Hepatitis Hepatitis acute Hepatitis toxic	Нера
Cholestasis Jaundice Hepatitis cholestatic jaundice cholestatic Yellow skin	CholJa
Hepatic failure Hepatitis fulminant Acute hepatic failure Hepatorenal failure	HepFail
Hepatotoxicity Hepatomegaly Hyperbilirubinaemia Hepatosplenomegaly	НерТох

## **Combining Predictions and Experimental Data**



Count the number of Adverse Event Group Consensus associations. If more than one is positive, the AERS Consensus is positive.

#### **OpenTox Consensus:**

Negative if both carcinogenicity and the micronucleus assay predictions are negative, OR if the Cramer Rule classification is Class I. Positive otherwise.

#### TCAMS Cytotoxicity:

Positive if > 30% growth inhibition at 10  $\mu M.$ 

TCAMS Antimalarial Activity: Positive if > 80% growth inhibition of P. Falciparum DD2 at 2  $\mu$ M.

# **Compound Prioritization Results**







# Example compounds

### "Safe"

#### TCMDC-131287:

- No predicted association with adverse events (consistent)
- Negative for carcinogenicity and mutagenicity
- No inhibition of HepG2 growth
- Strong inhibition of P. falciparum DD2 growth

### Ambiguous, Further Data Required



#### TCMDC-138057:

-Predicted association with many adverse events groups
-Positive for carcinogenicity and mutagenicity
-Considered safe (Class I) with Cramer rules
-Inhibition of HepG2 growth could not be measured
-Strong inhibition of P. falciparum DD2 growth

### "Toxic"



#### TCMDC-137245:

- Associated with 4 and 5 (out of 5) adverse events group by Pharmatrope and Leadscope, respectively
- Positive for carcinogenicity and mutagenicity, Cramer Class III
- 67% HepG2 inhibition (10 μM)
- 91% P. falciparum DD2 growth inhibition (at 2 μM)



### TCMDC-125641:

-No adverse event association predicted with Pharmatrope models -Strong association with all five adverse events groups predicted with the Leadscope models

-Negative for carcinogenicity and mutagenicity

-Intermediate inhibition of HepG2 growth (33% at 10  $\mu$ M)

-Strong inhibition of P. falciparum DD2 growth (100% at 2  $\mu$ M)

# The Building Blocks of SEURAT-



~ 70 research groups from European Universities, Public Research Institutes and Companies (more than 30% SMEs)





# The Building Blocks of SEURAT-

Scr P Tox

Stem cell differentiation for providing human-based organ specific target cells



C SMOS



• Identification and investigation of human biomarkers

Delivery of computational tools to predict the effects of



- NOTOX Development of systems biological tools for organotypic human cell cultures
- ToxBank Supporting integrated data analysis and servicing of alternative testing methods in toxicology
  - **COACH** Cluster level Coordinating and Support Action





### Our Infrastructure Vision for ToxBank supporting all steps of Predictive Toxicology Research based on Alternative Testing methods

Users access compounds, biological materials, data and models for experimental planning and integrated analysis of experimental results



OLIPA

THE EUROPEAN

This project will be jointly funded by COLIPA and the EC. Any opinions expressed in this slide are those of the author. COLIPA is not liable for any use that may be made of the information contained therein.

## **OpenTox InterAction Meeting 2011**

### **Innovation in Predictive Toxicology**

Modeling, Applications, REACH, Risk Assessment

9-12 August, 2011 Technical University of Munich, Germany

**Ca.** 80 attendees participated in workshop, knowledge cafés, conference, poster session

More Information at: www.opentox.org/meet/opentox2011

There will be an OpenTox 2012!



## **Collaborating Partners**

In Silico Toxicology, Switzerland Douglas Connect, Switzerland (Coordinator)

Ideaconsult, Bulgaria

Istituto Superiore di Sanità, Italy

Technical University of Munich, Germany



David Gallagher, UK

OpenTox

Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, Russia Albert Ludwigs University Freiburg, Germany

> National Technical University of Athens, Greece

Fraunhofer Institute for Toxicology & Experimental Medicine, Germany

Seascape Learning & JNU, India



## Our Funding Support...

OpenTox - An Open Source Predictive Toxicology Framework, www.opentox.org, is funded under the EU Seventh Framework Program: HEALTH-2007-1.3-3 Promotion, development, validation, acceptance and implementation of QSARs (Quantitative Structure-Activity Relationships) for toxicology Project Reference Number Health-F5-2008-200787 (2008-2011).

For more information, visit www.opentox.org

Contact: barry.hardy -(at)- douglasconnect.com <u>twitter.com/barryhardy</u> barryhardy.blogs.com



